# Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma

> **NCT07067346** · EARLY_PHASE1 · RECRUITING · sponsor: **Sichuan University** · enrollment: 10 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** IR-101

## Key facts

- **NCT ID:** NCT07067346
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-18
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07067346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07067346, "Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07067346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*